EXXON MOBIL CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EXXON MOBIL CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.24B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $349.59B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $344.58B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $413.68B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $285.64B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $181.50B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $264.94B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $290.21B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $244.36B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $200.63B | Feb 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $276.69B | Feb 23, 2022 |
| FY2021 | Dec 31, 2020 | $178.57B | Feb 23, 2022 |
| FY2021 | Dec 31, 2019 | $255.58B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $279.33B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $237.16B | Feb 26, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.84B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $33.68B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $36.01B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $55.74B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $23.04B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($22.44B) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $14.34B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $20.84B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $19.71B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $7.84B | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.00B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $900.00M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $824.00M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $843.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.02B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $1.21B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $1.12B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.06B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.06B | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.13B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $9.98B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $9.92B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $10.10B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $9.57B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $10.17B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $11.40B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $11.48B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $10.65B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $10.44B | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.97B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $55.02B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $55.37B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $76.80B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $48.13B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $14.67B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $29.72B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $36.01B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $30.07B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $22.08B | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.36B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $24.31B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $21.92B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $18.41B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $12.08B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $17.28B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $24.36B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $19.57B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $15.40B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $16.16B | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.98B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $453.48B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $376.32B | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | $369.07B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $338.92B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $332.75B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $362.60B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $346.20B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $348.69B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $330.31B | Feb 27, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.35B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $182.87B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $163.78B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $166.59B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $163.24B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $168.62B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $163.66B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $147.67B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $154.19B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $156.48B | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.39B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $263.71B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $204.80B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $195.05B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $168.58B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $157.15B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $191.65B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $191.79B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $187.69B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $167.33B | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $482.49B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $470.90B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $453.93B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $432.86B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $392.06B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $383.94B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $421.34B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $421.65B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $414.54B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $407.83B | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.68B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $23.03B | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $31.54B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $29.64B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.80B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $4.36B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $3.09B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $3.04B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.18B | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $3.66B | Feb 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 13 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (5) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 3 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | 13 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (5) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | 3 | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 1 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.18B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 4.35B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | 3.97B | Feb 18, 2026 |
| FY2025 | Dec 31, 2022 | 4.08B | Feb 18, 2026 |
| FY2024 | Dec 31, 2021 | 4.24B | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | 4.23B | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | 4.23B | Feb 22, 2023 |
| FY2021 | Dec 31, 2018 | 4.24B | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | 4.24B | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | 4.15B | Feb 26, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.23B | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $16.70B | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $14.94B | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $14.94B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $14.92B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $14.87B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $14.65B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $13.80B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $13.00B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $12.45B | Feb 27, 2019 |